TABLE 1.
Characteristics of the study population and self-reported antibiotic use in the past month, by sexual orientation, from a total of 14,775 STI clinic consultationsa
| Characteristic | Women (n = 7,419) | Heterosexual men (n = 5,007) | MSM (n = 2,349) | Pb | Total (n = 14,775) |
|---|---|---|---|---|---|
| Median age, yr (interquartile range) | 23 (20–30) | 25 (22–36) | 37 (25–48) | ** | 24 (21–37) |
| C. trachomatis diagnosis | |||||
| Any sitec | 10.6 (788) | 11.8 (593) | 9.2 (216) | ** | 10.8 (1,597) |
| Genitald | 10.2 (757) | 11.7 (588) | 3.2 (76) | ** | 9.6 (1,421) |
| Anorectald | 6.5 (136) | 0.9 (7) | 7.3 (162) | ** | 6.0 (305) |
| Oropharyngeald | 1.4 (22) | 0.2 (2) | 0.7 (16) | ** | 0.8 (40) |
| N. gonorrhoeae diagnosis | |||||
| Any sitec | 1.1 (82) | 1.0 (50) | 6.4 (150) | ** | 1.9 (282) |
| Genitald | 0.6 (45) | 0.6 (30) | 1.4 (32) | ** | 0.7 (107) |
| Anorectald | 0.7 (15) | 0.4 (3) | 4.0 (88) | ** | 2.1 (106) |
| Oropharyngeald | 2.7 (43) | 2.2 (19) | 3.4 (79) | 3.0 (141) | |
| HIV positivee | 0.2 (13) | 0.1 (7) | 9.2 (216) | 1.6 (236) | |
| Overall antibiotic use (past month) | 14.8 (1,099) | 8.5 (428) | 11.7 (274) | ** | 12.2 (1,801) |
| Antibiotic use per named indication | |||||
| Urinary tract infections | 3.1 (229) | 0.2 (12) | 0.3 (6) | ** | 1.7 (247) |
| Respiratory tract infections | 1.4 (105) | 1.1 (57) | 1.5 (35) | ** | 1.3 (197) |
| Other (non-STI) indications | 1.4 (102) | 1.4 (71) | 1.5 (36) | 1.4 (209) | |
| Unknown indications | 8.9 (663) | 5.8 (288) | 8.4 (197) | ** | 7.8 (1,148) |
| Any antibiotic agent reported | 4.5 (331) | 2.2 (109) | 4.3 (101) | ** | 3.7 (541) |
| Antibiotic use per named agent/classf | |||||
| Doxycycline | 0.6 (39) | 0.4 (20) | 0.8 (18) | 0.5 (77) | |
| Azithromycin | 0.4 (28) | 0.4 (17) | 0.6 (12) | 0.4 (57) | |
| Ofloxacin | 0.1 (4) | 0.1 (4) | 0 (0) | 0.1 (8) | |
| Amoxicillin | 1.1 (76) | 0.7 (31) | 1.5 (33) | ** | 1.0 (140) |
| Erythromycin | 0.1 (4) | 0 (0) | 0 (0) | 0 (4) | |
| Ceftriaxone | 0 (1) | 0 (1) | 0.2 (5) | ** | 0.1 (7) |
| Ciprofloxacin | 0.2 (12) | 0.2 (9) | 0.3 (6) | 0.2 (27) | |
| Any tetracyclines | 0.8 (50) | 0.5 (23) | 1.2 (26) | ** | 0.7 (99) |
| Any macrolides | 0.6 (38) | 0.4 (19) | 0.6 (12) | 0.5 (69) | |
| Any quinolones | 0.4 (24) | 0.4 (18) | 0.3 (7) | 0.3 (49) | |
| Any cephalosporins | 0 (3) | 0 (1) | 0.4 (8) | ** | 0.1 (12) |
| Any penicillins | 1.7 (112) | 0.9 (44) | 2.0 (44) | ** | 1.5 (200) |
| Nitrofurantoin/trimethoprim/fosfomycin | 1.5 (100) | 0.1 (3) | 0.1 (2) | ** | 0.8 (105) |
| Otherg | 0.6 (37) | 0.2 (9) | 0.3 (7) | * | 0.4 (53) |
a
Data are reported as percentages (numbers of subjects) unless otherwise indicated.
b
*, P < 0.05; **, P < 0.01 (by chi-square test on the difference between women, heterosexual men, and MSM [for age, nonparametric test]).
c
Including genital, anorectal, and/or oral diagnosis at current consultation.
d
The denominator includes only the tested individuals.
e
HIV diagnosed at current consultation or known HIV positive.
f
More than 1 agent could be named during a consultation.
g
Mainly metronidazole and (some) clindamycin.